跳转到主要内容
搜索

FDA 对 Lykos 的拒绝延缓了迷幻疗法的发展 — 但并未阻止其步伐

Certara’s Dr. Fran Brown, Senior Vice President of Drug Development Science, is quoted in this BioSpace article about the FDA’s Complete Response Letter for the Lykos Therapeutics’s MDMA therapy for PTSD. Read the article to get her thoughts on the gaps in Lykos’ data package and how psychedelic drug developers can avoid these pitfalls.

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software